check_circleStudy Completed
Vasomotor Symptoms as a sex hormone-dependent disorder in women and men, Hot flashes, Healthy volunteers
Bayer Identifier:
21756
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
A study to learn more about how the study treatment elinzanetant (or BAY3427080) moves into, through and out of the body, how safe it is and how it affects the body after taking single and multiple doses in healthy women aged 40 to 65 years
Trial purpose
Researchers are looking for a better way to treat men and women with vasomotor symptoms, a condition of having hot flashes caused by hormonal changes.
In women, these hormonal changes happen in the time around their menopause, the last period (menstrual cycle) a woman has. After the menopause, the ovaries produce less and less sex hormones as a result of the natural ageing process and related hormonal adaptations. The decrease in hormones produced can lead to various symptoms that may be troublesome. Vasomotor symptoms are also seen in men.
The study treatment, elinzanetant, is under development to treat symptoms caused by hormonal changes. It works by blocking a substance called neurokinin, which is thought to play a role in starting hot flashes.
Previous studies have been done. This study will provide information on how to use elinzanetant in Chinese people.
The main purpose of this study is to learn how much of the study treatment elinzanetant gets into the participants’ blood when a single dose is taken in healthy Chinese women.
To answer this question, the researchers will measure:
• The (average) total level of elinzanetant in the blood (also called AUC)
• The (average) highest level of elinzanetant in the blood (also called Cmax)
The researchers also want to learn how much elinzanetant gets into the blood when taken for 6 days in a row.
Dependent on the treatment group, the participants will either take elinzanetant or placebo. First, a single dose of two capsules is taken by mouth and later multiple doses once a day for another 6 days in a row are taken.
Each participant will be in the study for approximately 22 days including 7 treatment days in total. Participants will stay in-house for 16 days. In addition, one visit to the study site prior start and four visits after the in-house period are planned.
During the study, the study team will:
• Do physical examinations
• Take blood and urine samples
• Check vital signs
• Examine the participants’ heart health using electrocardiogram (ECG)
• Ask the participants questions about how they are feeling and what adverse events they are having.
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.
In women, these hormonal changes happen in the time around their menopause, the last period (menstrual cycle) a woman has. After the menopause, the ovaries produce less and less sex hormones as a result of the natural ageing process and related hormonal adaptations. The decrease in hormones produced can lead to various symptoms that may be troublesome. Vasomotor symptoms are also seen in men.
The study treatment, elinzanetant, is under development to treat symptoms caused by hormonal changes. It works by blocking a substance called neurokinin, which is thought to play a role in starting hot flashes.
Previous studies have been done. This study will provide information on how to use elinzanetant in Chinese people.
The main purpose of this study is to learn how much of the study treatment elinzanetant gets into the participants’ blood when a single dose is taken in healthy Chinese women.
To answer this question, the researchers will measure:
• The (average) total level of elinzanetant in the blood (also called AUC)
• The (average) highest level of elinzanetant in the blood (also called Cmax)
The researchers also want to learn how much elinzanetant gets into the blood when taken for 6 days in a row.
Dependent on the treatment group, the participants will either take elinzanetant or placebo. First, a single dose of two capsules is taken by mouth and later multiple doses once a day for another 6 days in a row are taken.
Each participant will be in the study for approximately 22 days including 7 treatment days in total. Participants will stay in-house for 16 days. In addition, one visit to the study site prior start and four visits after the in-house period are planned.
During the study, the study team will:
• Do physical examinations
• Take blood and urine samples
• Check vital signs
• Examine the participants’ heart health using electrocardiogram (ECG)
• Ask the participants questions about how they are feeling and what adverse events they are having.
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.
Key Participants Requirements
Sex
FemaleAge
40 - 65 YearsTrial summary
Enrollment Goal
16Trial Dates
May 2022 - July 2022Phase
Phase 1Could I Receive a placebo
YesProducts
BAY3427080Accepts Healthy Volunteer
YesWhere to participate
Status | Institution | Location |
---|---|---|
Completed | The First Affiliated Hospital of Guangzhou University of TCM | Guangzhou, 510405, China |
Primary Outcome
- Cmax: maximum observed drug concentration in measured matrix after single dose administrationdate_rangeTime Frame:From pre-dose up to 168 hours after first dosing
- AUC: area under the concentration vs. time curve from zero to infinity after single doseAUC(0-tlast) will be used as the main parameter if AUC cannot be reliably determineddate_rangeTime Frame:From pre-dose up to 168 hours after first dosing
- Cmax,md: maximum observed drug concentration in measured matrix after multiple dose administrationdate_rangeTime Frame:From pre-dose up to 180 hours after last dosing
- AUC(0-24)md: AUC from time 0 to 24 hours for multiple dosingdate_rangeTime Frame:From pre-dose up to 180 hours after last dosing
Secondary Outcome
- Number of participants with and severity of treatment-emergent adverse events (TEAEs)date_rangeTime Frame:From first dose of study intervention until follow-up visit on day 21
Trial design
Trial Type
InterventionalIntervention Type
DrugTrial Purpose
Basic ScienceAllocation
RandomizedBlinding
N/AAssignment
Parallel AssignmentTrial Arms
2